Kura Oncology Inc
KURAHealthcare|Biotechnology|USA
$11.44
-0.63 (-5.22%)
Tangible Book
$1.22
Earnings Power
$4.33
Upcoming Data Readouts (10)
Aug 2026
Est. completion
P1AML
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788n=171
Jan 2027
Est. completion
P1Solid Tumors With HRAS Alterations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410n=300
Jan 2027
Est. completion
P1Relapsed/Refractory KMT2A-r Acute Leukemia
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162n=20
Dec 2027
Est. completion
P1Gastrointestinal Stromal Tumor (GIST)
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246n=157
Oct 2028
Est. completion
P1P2Advanced Malignant Neoplasm
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336n=263
Dec 2028
Est. completion
P1P2Lymphoblastic Leukemia
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
NCT05848687n=90
Dec 2028
Est. completion
P1Refractory Acute Leukemia
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
NCT06397027n=22
Dec 2028
Est. completion
P1Acute Myeloid Leukemia
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
NCT06448013n=22
Apr 2030
Est. completion
P1Acute Myeloid Leukemia
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT05735184n=420
Nov 2031
Est. completion
P3Acute Myeloid Leukemia (AML)
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312n=1,300